A Phase II Clinical Trial of Chiglitazar for NASH

Summary

The study is to evaluate the efficacy and safety of chiglitazar monotherapy in patients with non-clcoholic steatohepatitis (NASH).

Timeline

Start

2022-03-21

Primary completion

2024-01-02

Completion

2024-01-02

Outcome

Met primary endpoint

release “steatohepatitis (NASH) was successfully completed with data cleaning and database locking on February 22, 2024. The primary efficacy endpoint of the trial has been achieved” chipscreen.com ↗

Drugs

Indications